Abstract
Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Current Pharmaceutical Design
Title:An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies
Volume: 23 Issue: 4
Author(s): Weronika Wasinska-Borowiec, Kaveh Abri Aghdam, Jukka Matias Saari and Andrzej Grzybowski
Affiliation:
Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Abstract: Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Export Options
About this article
Cite this article as:
Wasinska-Borowiec Weronika, Aghdam Abri Kaveh, Saari Matias Jukka and Grzybowski Andrzej, An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies, Current Pharmaceutical Design 2017; 23 (4) . https://dx.doi.org/10.2174/1381612823666170124113826
DOI https://dx.doi.org/10.2174/1381612823666170124113826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Pharmacologic Strategies to Protect the Liver from Ischemia- Reperfusion Injury
Recent Patents on Cardiovascular Drug Discovery Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology Mechanical Ventilation Following Cardiac Surgery in Children
Current Respiratory Medicine Reviews Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Future Prospects in Anti-Platelet Therapy: A Review of Potential P2Y12 and Thrombin Receptor Antagonists
Recent Patents on Cardiovascular Drug Discovery Cardiac Rehabilitation Outcome Following Percutaneous Coronary Intervention Compared to Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Heme Oxygenase-1 in Lung Disease
Current Drug Targets Influence of Lung Hyperinflation on Respiratory Muscles Pressures During a Submaximal Test in Patients With COPD: A Clinical Perspective
Current Respiratory Medicine Reviews Anaphylaxis to Pantoprazole: A Case Report and Prerequisite for Vigilant Prescribing Practises for Proton Pump Inhibitors
Current Drug Safety Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Profile of IKs During the Action Potential Questions the Therapeutic Value of IKs Blockade
Current Medicinal Chemistry Fullerenes for Applications in Biology and Medicine
Current Medicinal Chemistry Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology